Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium

Rhea-AI Summary

Cyteir Therapeutics (CYT) has announced a presentation on the mechanism of action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium on October 26, 2022. CYT-0851 is identified as an inhibitor of monocarboxylate transporter (MCT) activity, which disrupts glycolysis in cancer cells. Preliminary data was shared earlier in April 2022. The compound is currently in a Phase 1/2 clinical trial as a potential first-in-class therapy. Cyteir aims to identify biomarkers for patient selection to optimize treatment outcomes.

Positive

• Presentation of CYT-0851's mechanism at a prominent symposium may enhance visibility and credibility.
• Potential first-in-class status for CYT-0851 could lead to competitive advantages in the oncology market.
• Ongoing Phase 1/2 trials indicate progress in the drug development pipeline, important for investor confidence.

Negative

• Dependence on clinical trial success for drug approval introduces risk; results may not meet safety and efficacy standards.
• Ongoing global COVID-19 pandemic could potentially delay clinical trial processes and impact operational capabilities.

- Poster details the research into CYT-0851 mechanism of action and identification as an inhibitor of monocarboxylate transporter activity

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the company will be presenting a poster on the mechanism of action of CYT-0851 at the 34^th Annual EORTC-NCI-AACR Symposium at the poster session "Molecular Targeted Agents 1" on Wednesday, October 26, 2022 (Abstract No. 71). Cyteir shared preliminary evidence that CYT-0851 targeted monocarboxylate transporter (MCT) activity at an R&D Day in April 2022 and will provide additional mechanistic data on CYT-0851 at this symposium poster presentation.

“Elucidation of the mechanism of action of CYT-0851 as an inhibitor of monocarboxylate transporter activity has been an important accomplishment for the Cyteir Research team,” said Paul Secrist, PhD, Chief Scientific Officer of Cyteir. “By impairing monocarboxylate transporter-mediated lactate transport, CYT-0851 disrupts glycolysis, a key metabolic pathway shared broadly by cancer cells. This knowledge has allowed the team to sharpen its focus on identifying biomarkers to select the patients most likely to benefit from CYT-0851 treatment.”

“I am very proud of the Cyteir Research team for the speed with which they were able to pivot from a phenotypic screen to an understanding of the molecular target of CYT-0851, complementing our fast to the clinic development approach,” said Markus Renschler, MD, President and Chief Executive Officer of Cyteir. “These research findings may provide additional insights on the patient population who could benefit from CYT-0851 therapy.”

CYT-0851 is in a Phase 1/2 clinical trial as both a monotherapy and in combination with standard of care chemotherapy and has the potential to be a first-in-class MCT inhibitor. Translational analysis of patient samples is ongoing to confirm pharmacodynamic effects and to identify potential patient selection biomarkers. The April 2022 R&D Day can be accessed on demand in the Investor & Media section of the Cyteir website.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. At Cyteir, we employ an integrated target discovery approach that incorporates a critical evaluation of the target biology with internal and external information from a variety of genetic and chemical synthetic lethality screens to fuel our drug discovery and development pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a selective oral investigational drug currently in a Phase 1/2 clinical trial for hematologic malignancies and solid tumors. Follow Cyteir on social media: LinkedIn and Twitter and at www.cyteir.com.

Forward-Looking Statements

This press release contains “forward-looking statements” about Cyteir’s strategy, future plans, and prospects, including statements regarding the development of Cyteir’s compounds and potential expansion opportunities, regulatory strategy, and path for Cyteir’s compounds, and the expected timing and reporting of results of Cyteir’s preclinical and clinical studies. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “project,” “seek,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to: that Cyteir’s clinical trials may fail to demonstrate adequately the safety and efficacy of any of its drug candidates; that preclinical testing of Cyteir’s compounds may not be predictive of the results or success of clinical trials; that the preclinical and clinical development of Cyteir’s compounds may be delayed or otherwise take longer and/or cost more than planned; that Cyteir may be unable to initiate, enroll or complete clinical development of its compounds; that the continuing global outbreak of COVID-19 (including any resurgences or variants) may result in development or manufacturing delays, supply shortages, or shortages of qualified healthcare personnel; that synthetic lethality, as an emerging class of precision medicine targets, could result in negative perceptions of the efficacy, safety or tolerability of this class of targets, which could adversely affect our ability to conduct our business, advance our drug candidates or obtain regulatory approvals; and that Cyteir’s compounds may not receive regulatory approvals or become commercially successful products. These and other risks and uncertainties are identified under the heading “Risk Factors” in Cyteir’s most recent Annual Report on Form 10-K and other filings Cyteir has made and may make with the Securities and Exchange Commission ("SEC") in the future, available on the SEC's website at www.sec.gov.

The forward-looking statements contained in this press release are based on management's current views, plans, estimates, assumptions, and projections with respect to future events, and Cyteir does not undertake and specifically disclaims any obligation to update any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005227/en/

Lisa Hayes

Vice President, Investor Relations and Corporate Communications

908-868-8926

Lisa.Hayes@cyteir.com

Source: Cyteir Therapeutics

FAQ

What is the mechanism of action of CYT-0851 as presented by Cyteir Therapeutics?

CYT-0851 acts as an inhibitor of monocarboxylate transporter (MCT) activity, disrupting glycolysis in cancer cells.

When will the CYT-0851 poster presentation take place?

The poster presentation will occur on October 26, 2022, at the EORTC-NCI-AACR Symposium.

What stage is the CYT-0851 clinical trial currently in?

CYT-0851 is currently in a Phase 1/2 clinical trial.

What are the potential benefits of CYT-0851 therapy?

CYT-0851 aims to provide new treatment options for patients with hematologic malignancies and solid tumors.

What risks are associated with Cyteir Therapeutics' clinical trials?

Risks include the possibility of clinical trials failing to demonstrate adequate safety and efficacy, as well as potential delays caused by COVID-19.